Dopamine agonists can be used as conjunctive therapy with levodopa to potentiate an antiparkinsonian effect, to reduce the dosage needed for levodopa alone, and to overcome some of the adverse effects of long-terme use of levodopa, or as monotherapy in the early stage of the disease to delay introduction of levodopa.